Zürcher Nachrichten - Study shows how fast kilos return after ending weight-loss drugs

EUR -
AED 4.35335
AFN 77.050797
ALL 96.614026
AMD 452.873985
ANG 2.121943
AOA 1087.00321
ARS 1723.800654
AUD 1.702936
AWG 2.136666
AZN 2.019869
BAM 1.955248
BBD 2.406031
BDT 145.978765
BGN 1.990709
BHD 0.449191
BIF 3539.115218
BMD 1.18539
BND 1.512879
BOB 8.254703
BRL 6.231008
BSD 1.194568
BTN 109.699013
BWP 15.630651
BYN 3.402439
BYR 23233.647084
BZD 2.402531
CAD 1.615035
CDF 2684.909135
CHF 0.915881
CLF 0.026011
CLP 1027.058063
CNY 8.240537
CNH 8.248946
COP 4354.94563
CRC 591.535401
CUC 1.18539
CUP 31.412839
CVE 110.234327
CZK 24.334287
DJF 212.720809
DKK 7.470097
DOP 74.383698
DZD 153.702477
EGP 55.903178
ERN 17.780852
ETB 185.572763
FJD 2.613371
FKP 0.859325
GBP 0.865754
GEL 3.194674
GGP 0.859325
GHS 12.974143
GIP 0.859325
GMD 86.533903
GNF 10372.164298
GTQ 9.16245
GYD 249.920458
HKD 9.257838
HNL 31.365884
HRK 7.536597
HTG 156.336498
HUF 381.328619
IDR 19883.141804
ILS 3.663335
IMP 0.859325
INR 108.679593
IQD 1553.453801
IRR 49934.560565
ISK 144.985527
JEP 0.859325
JMD 187.197911
JOD 0.840489
JPY 183.433247
KES 152.915746
KGS 103.662825
KHR 4768.236408
KMF 491.93733
KPW 1066.949348
KRW 1719.752641
KWD 0.36382
KYD 0.995519
KZT 600.800289
LAK 25485.888797
LBP 101410.128375
LKR 369.427204
LRD 219.593979
LSL 19.132649
LTL 3.500149
LVL 0.717031
LYD 7.495914
MAD 10.835985
MDL 20.092409
MGA 5260.173275
MKD 61.631889
MMK 2489.374007
MNT 4229.125697
MOP 9.606327
MRU 47.30937
MUR 53.852723
MVR 18.32658
MWK 2059.023112
MXN 20.70407
MYR 4.672854
MZN 75.580924
NAD 18.967522
NGN 1643.520192
NIO 43.508231
NOK 11.437875
NPR 175.519161
NZD 1.96876
OMR 0.458133
PAB 1.194573
PEN 3.994177
PGK 5.066955
PHP 69.837307
PKR 331.998194
PLN 4.215189
PYG 8001.773454
QAR 4.316051
RON 5.097064
RSD 117.111851
RUB 90.544129
RWF 1742.915022
SAR 4.446506
SBD 9.544303
SCR 17.200951
SDG 713.016537
SEK 10.580086
SGD 1.505332
SHP 0.88935
SLE 28.834661
SLL 24857.038036
SOS 677.454816
SRD 45.104693
STD 24535.182964
STN 24.493185
SVC 10.452048
SYP 13109.911225
SZL 19.132635
THB 37.411351
TJS 11.151397
TMT 4.148866
TND 3.37248
TOP 2.854135
TRY 51.47818
TTD 8.110743
TWD 37.456003
TZS 3052.380052
UAH 51.199753
UGX 4270.811618
USD 1.18539
UYU 46.357101
UZS 14603.874776
VES 410.075543
VND 30749.020682
VUV 141.78282
WST 3.21762
XAF 655.774526
XAG 0.014004
XAU 0.000244
XCD 3.203577
XCG 2.153028
XDR 0.815573
XOF 655.774526
XPF 119.331742
YER 282.508153
ZAR 19.136335
ZMK 10669.938133
ZMW 23.443477
ZWL 381.695147
  • SCS

    0.0200

    16.14

    +0.12%

  • RBGPF

    1.3800

    83.78

    +1.65%

  • BCC

    0.5100

    80.81

    +0.63%

  • CMSD

    -0.0400

    24.05

    -0.17%

  • RYCEF

    -0.4300

    16

    -2.69%

  • RIO

    -4.1000

    91.03

    -4.5%

  • CMSC

    0.0500

    23.76

    +0.21%

  • BCE

    0.3700

    25.86

    +1.43%

  • RELX

    -0.3700

    35.8

    -1.03%

  • BTI

    0.4600

    60.68

    +0.76%

  • NGG

    0.2000

    85.27

    +0.23%

  • GSK

    0.9400

    51.6

    +1.82%

  • VOD

    -0.0600

    14.65

    -0.41%

  • JRI

    0.1400

    13.08

    +1.07%

  • AZN

    0.1800

    92.77

    +0.19%

  • BP

    -0.1600

    37.88

    -0.42%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: Armend NIMANI - AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

A.Ferraro--NZN